Nanoscope Therapeutics Announces Presentation of Key Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa at the ARVO Annual Meeting

100% (18/18) MCO-010 patients experienced a clinically meaningful improvement in vision-guided mobility (MLYMT), near-field object recognition (MLSDT) or visual acuity (BCVA) (p=0.007 vs sham) 94.4% (17/18) MCO-010 patients showed vision improvement in the MLYMT or BCVA (p=0.008 vs sham)…